Recently, a cogent study demonstrated that the extent of MGMT methylation is a predictive marker for progression-free survival (PFS) of glioma patients harboring IDH mutations with TMZ treatment but not radiotherapy [51]. The gene discussed is IDH1; the disease is central nervous system cancer.